Crossmark

CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma

Crossref DOI link: https://doi.org/10.1186/s12885-018-4180-5

Published Online: 2018-03-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schlüter, Anke

Weller, Patrick

Kanaan, Oliver

Nel, Ivonne

Heusgen, Lukas

Höing, Benedikt

Haßkamp, Pia

Zander, Sebastian

Mandapathil, Magis

Dominas, Nina

Arnolds, Judith

Stuck, Boris A.

Lang, Stephan

Bankfalvi, Agnes

Brandau, Sven https://orcid.org/0000-0002-2702-4163
License Information

Text and Data Mining valid from 2018-03-09
More Information

Article History

Received: 15 December 2016

Accepted: 6 March 2018

First Online: 9 March 2018

Ethics approval and consent to participate

: The study was approved by the local ethics committee of the Medical Faculty of the University Duisburg-Essen (12–5192-BO) and was performed according to Declaration of Helsinki. Based on the retrospective and anonymous character of the study the approval contained a waiver for written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.